

The University of Akron

IdeaExchange@UAkron

Williams Honors College, Honors Research
Projects

The Dr. Gary B. and Pamela S. Williams Honors
College

Spring 2022

Repurposing human α -defensin 6, an antimicrobial peptide, as a beta amyloid inhibitor

Eleanor Plaster
emp86@uakron.edu

Follow this and additional works at: https://ideaexchange.uakron.edu/honors_research_projects



Part of the [Biochemical and Biomolecular Engineering Commons](#)

Please take a moment to share how this work helps you [through this survey](#). Your feedback will be important as we plan further development of our repository.

Recommended Citation

Plaster, Eleanor, "Repurposing human α -defensin 6, an antimicrobial peptide, as a beta amyloid inhibitor" (2022). *Williams Honors College, Honors Research Projects*. 1514.

https://ideaexchange.uakron.edu/honors_research_projects/1514

This Dissertation/Thesis is brought to you for free and open access by The Dr. Gary B. and Pamela S. Williams Honors College at IdeaExchange@UAkron, the institutional repository of The University of Akron in Akron, Ohio, USA. It has been accepted for inclusion in Williams Honors College, Honors Research Projects by an authorized administrator of IdeaExchange@UAkron. For more information, please contact mjon@uakron.edu, uapress@uakron.edu.

Revised Executive Summary

Alzheimer's disease (AD), experienced worldwide by around 50 million people, is the most common neurodegenerative disease. While the pathological mechanism of AD remains unclear, it is well accepted that the "amyloid cascade hypothesis" is one of the most significant causes of AD. Therefore, many beta amyloid (A β) inhibitors, including small organic molecules, nanoparticles, polymers, and mimetic peptides, have been developed to interfere with A β aggregation. However, none of these A β inhibitors have successfully passed clinical trials because of their low efficiency, difficulties crossing the blood-brain barrier, low biocompatibility, and high toxicity. Therefore, in this work, a "like interacts with like" hypothesis was proposed to discover peptide-based A β inhibitors with a β -sheet motif. Compared with other types of A β inhibitors, peptide-based A β inhibitors possess several intrinsic advantages including good biocompatibility, ease of synthesis and modification, controllable folding structures, and high binding affinity to targets. From a structure viewpoint, due to the conformationally similar β -sheet motifs, A β and inhibitors are likely to interact with each other to form non-toxic A β -inhibitor aggregates, thus preventing A β -A β self-interaction.

Considering that (1) human α -defensin 6 (HD-6) is an intestinal defensin that is made by intestinal Paneth cells, making communication between the brain and intestines possible via the gut-brain axis; (2) HD-6 is a cationic peptide that is able to electrostatically interact with A β ; and (3) HD-6 contains β -sheet segments, which is essential to interact with A β via the "like interacts with like" hypothesis, HD-6 was repurposed to study its ability to act as a A β inhibitor.

Collective data from Thioflavin T (ThT) assays, circular dichroism (CD) spectroscopy, and atomic force microscopy (AFM) showed that HD-6 exhibited surprising inhibition ability by slowing the A β aggregation rate, delaying secondary structure transition, and reducing A β fibril formation. In addition, cell assays including lactate dehydrogenase (LDH) assays and 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays suggested that HD-6 can protect neurons from A β -induced toxicity. These findings therefore indicate the potential role of HD-6 as a promising therapeutic agent for the prevention and treatment of AD.